Results 111 to 120 of about 89,075 (280)

Surgery for cholangiocarcinoma

Liver international (Print), 2019
Surgical resection is the only potentially curative treatment for patients with cholangiocarcinoma. For both perihilar cholangiocarcinoma (pCCA) and intrahepatic cholangiocarcinoma (iCCA), 5‐year overall survival of about 30% has been reported in large ...
U. Cillo, C. Fondevila, M. Donadon, E. Gringeri, F. Mocchegiani, H. Schlitt, J. Ijzermans, M. Vivarelli, K. Zieniewicz, S. O. Olde Damink, B. Groot Koerkamp   +10 more
semanticscholar   +1 more source

Hilar cholangiocarcinoma

World Journal of Gastrointestinal Oncology, 2013
Hilar cholangiocarcinoma (HC) is a rare tumor. It accounts for 2/3 of the tumors of the biliary tract. Untreated, prognosis is very poor. Surgery is the only therapy that offers the possibility of cure but is technically very complex. With recent improvements in the therapeutic strategies applied by multidisciplinary teams, survival rates in the ...
openaire   +2 more sources

Beyond a Conduit: The Evolution of Functional Biliary Stents From Active Intervention to Enabling Platforms

iNew Medicine, EarlyView.
This review traces the evolution of functional biliary stents, outlining the paradigm shift from “active intervention” strategies that target stent failure to next‐generation “enabling platforms.” These platforms leverage biodegradable materials, 3D/4D printing, and smart sensors to achieve personalized, regenerative, and theranostic solutions ...
Muhan Li, Xu Liu, Xin Ye, Zhixia Dong, Xinjian Wan   +4 more
wiley   +1 more source

Roles of Zinc Finger Protein 423 in Proliferation and Invasion of Cholangiocarcinoma through Oxidative Stress

Biomolecules, 2019
Zinc finger protein 423 (ZNF423) is a transcriptional factor involved in the development and progression of cancers but has not yet been examined in cholangiocarcinoma (CCA), an oxidative stress-driven cancer of biliary epithelium.
Timpika Chaiprasert, Napat Armartmuntree, Anchalee Techasen, Chadamas Sakonsinsiri, Somchai Pinlaor, Piti Ungarreevittaya, Narong Khuntikeo, Nisana Namwat, Raynoo Thanan   +8 more
doaj   +1 more source

Chinese pan‐cancer patient genomic characteristics: A comprehensive analysis based on the National Cancer Center–Clinical Diagnostics Knowledgebase real‐world clinical sequencing cohort

Interdisciplinary Medicine, EarlyView.
We assembled National Cancer Center–Clinical Diagnostics Knowledgebase, a clinical genomic knowledgebase of 6935 tumors with matched normal samples, revealing key somatic alterations and actionable variants (70.2% of the cohort). Enrichment of certain different gene mutations was observed between Chinese and American populations, along with a strong ...
Hongrui Li, Shun Wang, Guowei Zhao, Jiangtao Li, Xin Li, Bingning Wang, Yi Zhang, Mengfei Yao, Lei Guo, Jianming Ying, Wenbin Li   +10 more
wiley   +1 more source

Cholangiocarcinoma [PDF]

Visceral Medicine, 2016
Alfred, Königsrainer, Nisar P, Malek
openaire   +3 more sources

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

The Lancet Oncology, 2020
G. Abou-Alfa, V. Sahai, A. Hollebecque, G. Vaccaro, D. Melisi, R. Al-Rajabi, A. Paulson, M. Borad, D. Gallinson, A. Murphy, D. Oh, E. Dotan, D. Catenacci, E. Van Cutsem, T. Ji, C. Lihou, H. Zhen, L. Féliz, A. Vogel   +18 more
semanticscholar   +1 more source

Neoadjuvant Chemotherapy With Gemcitabine/Cisplatin/S‐1 for Resectable Biliary Tract Cancer With FDG‐PET‐Positive Lymph Node Metastasis (KHBO1201): A Multicenter Phase II Trial

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Purpose To evaluate the safety and efficacy of neoadjuvant gemcitabine, cisplatin, and S‐1 (GCS) chemotherapy for resectable biliary tract cancer (BTC) and FDG‐PET‐positive lymph nodes in a multicenter phase II study (KHBO1201). Methods Patients with resectable BTC (intrahepatic/extrahepatic bile duct, gallbladder, or ampullary cancers) and ...
Satoshi Ogiso, Etsuro Hatano, Satoru Seo, Masashi Kanai, Shogo Kobayashi, Hiroshi Wada, Hidetoshi Eguchi, Tatsuya Higashi, Hiroaki Nagano, Tatsuya Ioka   +9 more
wiley   +1 more source

Epidemiology of cholangiocarcinoma.

European Journal of Surgical Oncology, 2023
M. Qurashi, Mathew Vithayathil, Shahid Khan   +2 more
semanticscholar   +1 more source

Multicenter Validation Study of the Clinical Diagnostic Criteria for IgG4‐Related Sclerosing Cholangitis 2020 in Japan

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Background The diagnostic performance of clinical diagnostic criteria for IgG4‐related sclerosing cholangitis 2020 (IgG4‐SC2020) has not been fully validated since its proposal as a revision of the 2012 criteria (IgG4‐SC2012). Methods We conducted a multicenter validation study to evaluate the diagnostic performance of IgG4‐SC2020 using ...
Itaru Naitoh, Takahiro Nakazawa, Kensuke Kubota, Takayoshi Nishino, Akira Nakamura, Dai Inoue, Takanori Sano, Kazuhiro Kikuta, Yusuke Kurita, Kazuro Chiba, Tsukasa Ikeura, Hiroyuki Matsubayashi, Takuya Ishikawa, Masaki Kuwatani, Terumi Kamisawa, Ichiro Yasuda, Mitsuhiro Kawano, Atsushi Masamune, Japan Pancreatitis Study Group, Yoko Abe, Atsushi Irisawa, Hiroyuki Tanaka, Eizaburo Ohno, Tatsuru Maruo, Toshiharu Ueki, Rei Suzuki, Tadayuki Takagi, Hiromasa Ohira, Shirou Tanoue, Akio Ido, Takahiro Komori, Kayashima Atsuo, Masayasu Horibe, Eisuke Iwasaki, Masahiro Tsujimae, Yuzo Kodama, Kazushige Uchida, Masayuki Ueno, Kenji Notohara, Shotaro Kakehashi, Nao Fujimori, Eiji Nakatani, Yasuki Hori, Michihiro Yoshida, Hiroki Kawashima, Kazunao Hayashi, Shuji Terai, Kosaku Morimoto, Ryosuke Sato, Kazuyuki Matsumoto, Hironari Kato, Yoshiharu Masaki, Hiroshi Nakase, Toshihiko Arizumi, Atsushi Tanaka, Ryotaro Matusmoto, Tetsuya Takikawa, Ryosuke Tonozuka, Takao Itoi, Kenji Hirano, Nobuhiko Hayashi   +60 more
wiley   +1 more source